Global Trust Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Global Trust Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-16	Closed	-$1K	–	389
2020 Q4	$1K	Hold	16	–	–	﹤0.01%	371
2020 Q3	$1K	Hold	16	–	–	﹤0.01%	333
2020 Q2	$2K	Hold	16	–	–	﹤0.01%	294
2020 Q1	$1K	Hold	16	–	–	﹤0.01%	321
2019 Q4	$1K	Hold	16	–	–	﹤0.01%	354
2019 Q3	$1K	Hold	16	–	–	﹤0.01%	328
2019 Q2	$1K	Hold	16	–	–	﹤0.01%	372
2019 Q1	$1K	Hold	16	–	–	﹤0.01%	348
2018 Q4	$1K	Hold	16	–	–	﹤0.01%	357
2018 Q3	$2K	Buy	+16	New	+$1.6K	﹤0.01%	376

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Global Trust Asset Management's BMRN Position: Q1 2021 in Review

Global Trust Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 16 shares — an estimated $1K sold.

Global Trust Asset Management first reported a position in BMRN in Q3 2018 and held it in 10 quarters. The position peaked at $2K in Q2 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Global Trust Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Global Trust Asset Management sold 16 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $1K.
Global Trust Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 10 quarters.
Global Trust Asset Management's BioMarin Pharmaceuticals position peaked at $2K in Q2 2020.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Global Trust Asset Management's 13F filing for Q1 2021, filed 14 Apr 2021.